This “Periodontitis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Periodontitis Understanding
Periodontitis is a gum disease. It is a chronic inflammatory disease that is triggered by bacterial microorganisms and involves a severe chronic inflammation that causes the destruction of the tooth-supporting apparatus and can lead to tooth loss. It can also lead to other health problems. Periodontitis always begins with inflammation of the gums, known as gingivitis. This inflammation - usually involving reddened or swollen gums and bleeding when brushing teeth or biting on food - is the body's response to bacteria that have been allowed to accumulate on the teeth. This inflammation can then spread to below the gums and along the roots of the teeth. This can cause permanent damage to the tissues (or “periodontal ligament”) around the teeth and to the supporting bone. Teeth start to loosen and can eventually be lost. This can then lead to problems with chewing food and with speaking, as well as causing aesthetic damage to your smile.
"Periodontitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Periodontitis pipeline landscape is provided which includes the disease overview and Periodontitis treatment guidelines. The assessment part of the report embraces, in depth Periodontitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Periodontitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Periodontitis R&D. The therapies under development are focused on novel approaches to treat/improve Periodontitis.
This segment of the Periodontitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AMY-101 is a novel complement C3-targeted therapeutic based on the 3rd-generation compstatin analog Cp40. Compstatins are synthetic cyclic peptides with strong affinity and selectivity for human and primate C3, discovered at the University of Pennsylvania by Professor John Lambris and his team. Compstatins inhibit complement centrally, at the level of C3, and interrupt all downstream pathways of the complement activation cascade.
ST266 is a cell-free biologic containing hundreds of proteins and other factors involved in cellular healing, neuroprotection, and modulation of inflammation. ST266 is produced by collecting proteins and other factors secreted by a novel population of cells generated by a proprietary method of culturing amnion-derived epithelial cells collected from full term placentas which are normally discarded after birth. This secretome contains physiologic levels of multiple growth factors and cytokines and stimulates a variety of anti-inflammatory and neuroprotective responses in preclinical studies.
This segment of the report provides insights about the different Periodontitis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Periodontitis. The companies which have their Periodontitis drug candidates in the most advanced stage, i.e. phase II include, Amyndas Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Periodontitis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Periodontitis drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Periodontitis Understanding
Periodontitis: Overview
Periodontitis is a gum disease. It is a chronic inflammatory disease that is triggered by bacterial microorganisms and involves a severe chronic inflammation that causes the destruction of the tooth-supporting apparatus and can lead to tooth loss. It can also lead to other health problems. Periodontitis always begins with inflammation of the gums, known as gingivitis. This inflammation - usually involving reddened or swollen gums and bleeding when brushing teeth or biting on food - is the body's response to bacteria that have been allowed to accumulate on the teeth. This inflammation can then spread to below the gums and along the roots of the teeth. This can cause permanent damage to the tissues (or “periodontal ligament”) around the teeth and to the supporting bone. Teeth start to loosen and can eventually be lost. This can then lead to problems with chewing food and with speaking, as well as causing aesthetic damage to your smile.
"Periodontitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Periodontitis pipeline landscape is provided which includes the disease overview and Periodontitis treatment guidelines. The assessment part of the report embraces, in depth Periodontitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Periodontitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Periodontitis R&D. The therapies under development are focused on novel approaches to treat/improve Periodontitis.
Periodontitis Emerging Drugs Chapters
This segment of the Periodontitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Periodontitis Emerging Drugs
AMY-101: Amyndas Pharmaceuticals
AMY-101 is a novel complement C3-targeted therapeutic based on the 3rd-generation compstatin analog Cp40. Compstatins are synthetic cyclic peptides with strong affinity and selectivity for human and primate C3, discovered at the University of Pennsylvania by Professor John Lambris and his team. Compstatins inhibit complement centrally, at the level of C3, and interrupt all downstream pathways of the complement activation cascade.
ST266: Noveome Biotherapeutics
ST266 is a cell-free biologic containing hundreds of proteins and other factors involved in cellular healing, neuroprotection, and modulation of inflammation. ST266 is produced by collecting proteins and other factors secreted by a novel population of cells generated by a proprietary method of culturing amnion-derived epithelial cells collected from full term placentas which are normally discarded after birth. This secretome contains physiologic levels of multiple growth factors and cytokines and stimulates a variety of anti-inflammatory and neuroprotective responses in preclinical studies.
Periodontitis: Therapeutic Assessment
This segment of the report provides insights about the different Periodontitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Periodontitis
There are approx. 5+ key companies which are developing the therapies for Periodontitis. The companies which have their Periodontitis drug candidates in the most advanced stage, i.e. phase II include, Amyndas Pharmaceuticals.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Periodontitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Periodontitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Periodontitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Periodontitis drugs.
Periodontitis Report Insights
- Periodontitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Periodontitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Periodontitis drugs?
- How many Periodontitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Periodontitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Periodontitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Periodontitis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Amyndas Pharmaceuticals
- Noveome
- Vaxcyte
- Geistlich Pharma AG
- AngioLab, Inc.
- CSL behring
- LTN Pharm
Key Products
- AMY-101
- ST 266
- VAX PG
- PerioSept
- AL102-PDT
- POD CRC-OHS
- Myc 102
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Periodontitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Periodontitis - Analytical Perspective
Mid Stage Products (Phase II)
- Comparative Analysis
AMY-101: Amyndas Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
POD CRC-OHS: CSL behring
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Periodontitis Key Companies
Periodontitis Key Products
Periodontitis- Unmet Needs
Periodontitis- Market Drivers and Barriers
Periodontitis- Future Perspectives and Conclusion
Periodontitis Analyst Views
Periodontitis Key Companies
AppendixList of Tables
Table 1 Total Products for Periodontitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Periodontitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amyndas Pharmaceuticals
- Noveome
- Vaxcyte
- Geistlich Pharma AG
- AngioLab, Inc.
- CSL behring
- LTN Pharm
